Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Debt-to-Equity : 0.33 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Yichang HEC ChangJiang Pharmaceutical Co Debt-to-Equity?

Yichang HEC ChangJiang Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$2,537 Mil. Yichang HEC ChangJiang Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$317 Mil. Yichang HEC ChangJiang Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$8,680 Mil. Yichang HEC ChangJiang Pharmaceutical Co's debt to equity for the quarter that ended in Dec. 2023 was 0.33.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Yichang HEC ChangJiang Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

HKSE:01558' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.44 Max: 1.5
Current: 0.33

During the past 10 years, the highest Debt-to-Equity Ratio of Yichang HEC ChangJiang Pharmaceutical Co was 1.50. The lowest was 0.01. And the median was 0.44.

HKSE:01558's Debt-to-Equity is ranked worse than
53% of 851 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs HKSE:01558: 0.33

Yichang HEC ChangJiang Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Yichang HEC ChangJiang Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yichang HEC ChangJiang Pharmaceutical Co Debt-to-Equity Chart

Yichang HEC ChangJiang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.69

0.62

0.55

0.65

0.33

Yichang HEC ChangJiang Pharmaceutical Co Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial														0.55	0.62	0.65	0.65	0.33

Competitive Comparison of Yichang HEC ChangJiang Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Yichang HEC ChangJiang Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yichang HEC ChangJiang Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Yichang HEC ChangJiang Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Yichang HEC ChangJiang Pharmaceutical Co's Debt-to-Equity falls into.

Yichang HEC ChangJiang Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Yichang HEC ChangJiang Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2537.432	+	316.595)	/	8679.697
	=	0.33

Yichang HEC ChangJiang Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2537.432	+	316.595)	/	8679.697
	=	0.33

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Yichang HEC ChangJiang Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Yichang HEC ChangJiang Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yichang HEC ChangJiang Pharmaceutical Co Ltd (HKSE:01558) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

No. 38 Binjiang Road, Yidu, Hubei Province, Yichang, CHN

Website

http://www.hec-changjiang.com

Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic, and cardiovascular diseases. The company's key revenue driver is the anti-viral product division, which manufactures its key product, Kewei. It is one of the leading products in China's anti-influenza market. Its other products include Ertongshu, Oumeining, Olmesartan Tablets, and Clarithromycin Tablets.

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Headlines

No Headlines